Medicine and Dentistry
Adult
8%
Adverse Event
16%
Amaurosis
100%
Caregiver
8%
Chronic Inflammatory Demyelinating Polyneuropathy
100%
Drug Megadose
50%
Human Albumin
8%
Immunoglobulin
100%
Inpatient
8%
Intention-to-Treat Analysis
16%
Low Drug Dose
58%
Maintenance Therapy
100%
Patient
75%
Personnel
8%
Placebo
100%
Polyneuropathy
8%
Recurrence Risk
8%
Relapse
8%
Risk Reduction
8%
Skin Allergy
8%
Therapeutic Procedure
25%
Voice
8%
Nursing and Health Professions
Adverse Event
16%
Blindness
100%
Chronic Inflammatory Demyelinating Polyneuropathy
100%
Dose
16%
Drug Megadose
50%
Human Albumin
8%
Immunoglobulin
100%
Intention to Treat Analysis
16%
Low Drug Dose
58%
Maintenance Therapy
100%
Placebo
100%
Polyneuropathy
8%
Randomization
8%
Recurrence Risk
8%
Relapse
8%
Skin Allergy
8%
INIS
administration
6%
adults
6%
albumins
6%
assignments
6%
australia
6%
comparative evaluations
6%
delivery
6%
doses
100%
europe
6%
humans
6%
immunoglobulins
100%
inflammation
100%
israel
6%
japan
20%
maintenance
100%
north america
6%
patients
66%
personnel
6%
reduction
6%
risks
6%
size
6%
skin
6%
solutions
13%
Immunology and Microbiology
Chronic Inflammatory Demyelinating Polyneuropathy
100%
Dose
16%
Drug Megadose
50%
Intravenous Immunoglobulin
100%
Low Drug Dose
58%
Reduction (Chemistry)
8%
Skin Allergy
8%
Solution and Solubility
16%
Voice
8%
Pharmacology, Toxicology and Pharmaceutical Science
Adverse Event
16%
Blindness
100%
Chronic Inflammatory Demyelinating Polyneuropathy
100%
Human Albumin
8%
Immunoglobulin
100%
Polyneuropathy
8%
Recurrence Risk
8%
Relapse
8%
Skin Allergy
8%